Member Info for George-Inn

To my position and have been. More good news no doubt plus official release H1yet come and official launch for the Bausch product and with any good sales into year -end will lift expectations and then theirs the release for brain cancer interim. Much more on the way and with a bit of a push 100p is in the works maybe by end of year.

SilverKnight - Agreed and do yourself a bit of a favor and review the story of another pharma M/C company with an overnight expansion of unheard of gains. See the story on Aquinox Pharmaceuticals, then look for the similarities, it will astound you with the possibilities here before us. I continue to add at these depressed levels.

Hoping for s little upward movement next week. Not sure what the catalyst will be but feel it's time now that the 26.00p is stable and time to move ahead. So let's see what happens.

As do I and I continue from time to time take up another position and add. Agree states must be ready for a pop and wouldn't be surprised if August didn't have a gem of a surprise release, of news or something. But there should at least be the official sales launch for the Bausch product, and hope good news on clinical in Q3.

Taking a most in-depth read here I'd say that we have a bit of more news coming during this Q3 perhaps from both non-dilutive financing, maybe additional news on the official sales launch for the added product which will certainly bolster H2 sales numbers as well as positive read on early clinical from MTD201. Even if the newest product added from Bausch brings in only £100,000 in additional sales during H2 that might ensure a beat on the numbers and YoY for '18. All very exciting as we look for additional news any surprises would also be positive. One item to not is that the share index state side must rise $1.00 to avoid any issues regarding listings. Are there any others on this board with ideas as to what else may come along in H2?

I'd agree with your reading and will add that as the time draws near for the posting of the early clinical data on oncology results the stock should pep up and prepare for a hard run higher. Craig said late Q3 or early Q4 so that provides a couple of months additional time to continue loading shares at highly discounted terms. I'm a buyer and continue to load, but yes there is a risk to this but point is how much?

I'd suspect about this time that Nick has been crunching the numbers for 1H and making a determination as to the financial status of the company. I'd be very surprised if the states weren't continuing to progress toward profitability and would hope that prudent management of funds continue as well. What will be interesting to see is if any additional information is released regarding any of the current trials, and progression of each. I'd suspect we're bottoming or have bottomed in share price and as the interims loom we may begin uptick in volume and price. All speculation on my part, and I continue to load at these depressed levels. Good luck and cheers to all...

An official welcome to the new CEO and Board Director of Midatech. Welcome Craig, now that its official I am certain that more news is to come. The AGM is to be held later this month and I should expect that in addition to recap of 2017 there will be additional news. On the surface and looking at his previous roles, Craig does not appear as though he'll be a "passive" leader, but more of a "passionate" leader who's deeply invested in the success of this company. For that the shareholders should be grateful to have such a dedicated management team. Looking forward to the future successes.. GLTA

I'd have to agree 100% and in the interim I continue adding to an already large position. I would expect to see several runs of 150% and higher between late 2018 - 2022 and then capitalize on them. The technology is there, the pipeline is there, the management to see it through is there, and most important is that the patents are there. Those patents and this company are worth a small fortune...stay tuned.

Perhaps but when averaging up or down the slide in favor of a steady and mature approach to investing. 25p - 30p range is adequate for my needs to continue loading. Development, delivery and trial results coming later this summer with top-line and efficacy profiles. Wouldn't bet against "extremely positive" results as a possibility and hard pop when released with results showing up on the radar's of larger pharma's. I take it all in stride as I continue the relentless loading of shares.

I don't get the term speeding ticket? As for the placing idea it's not needed nor even warranted. When early positive clinical results come in two things happen. First the share price should pop hard and remain stable and secondly the 2nd tranche of funds 8 million will be released to fund the remaining trial(s) and funding from non-dilutive stance could come as a result. Just don't see any value in suggesting a placing when there's no merit to it. Just my two cent's as a long term investor.

Adding to my share base. I'm not here for the flash trade nor the one big gap up, or spike but rather a regular who's been here through the good and tough times. Change in management seems promising, I like Jim but the style and enthusiasm waned on the investors it seems. Craig has passion, almost a chip on his shoulder with something to prove. That sort of tenacity will get you results, and results are why I am here as an investor and not a day trader. I will keep adding to my stockpile as I've been doing for quite some time. Good luck to all here regardless of your investment strategy. I like and trust the new team, the directors and the planning. It takes time to grow a shire or Jazz and it's possible that Midatech is just that kind of company, with that special technology to achieve greatness.

Yes we do know that Woodford sold them and what a drag that's taken on the share price since late last year. Not even sure if he's done selling yet either. So it has to remain above the $1 limit for 10 consecutive trading days in the 180 day period after the notification. Well that seems feasible and simple enough but it's going to take a good showing to do that. And finally if you say 300% undervalued at mo. then it would be much more than that if the �200 sales were generated. So what would you estimate the share price to be if that occurs? Lot's of speculation but just asking various opinions based on your number here.

Strong show of support at 25p so hopefully the bottom is in and we can begin to ascend in price into the summer and listening to Craig on the call it would seem as though they will post not less than 3 - 4 additional updates later this year regarding the clinical trials. So each update has the potential to be a value inflection point which means the potential to be a positive catalyst to the share price, so maybe that's why we see buyers stepping in. Good call Craig and Nick it was upbeat, positive and meaningful. keep up the momentum and we'll get back to some growth.

They've filed the Form 20-F today and also noticed stateside that the listing on their exchange for Nasdaq is governed more than here with very specific terms to remain listed accordingly. Midatech U.S division must retain all terms to remain listed in good standing and one of those terms to maintain a minimum of $1.00 U.S per share or ADR and if not then de-listing on their exchange will be an issue to deal with. I believe that the de-listing notification comes at the 30 business days below that amount, and then the company has six months to remediate the infraction. I am not well versed in this exchange rules for their listings but from what I've reviewed it seems to be that a notification from their exchange is forth-coming if the share price is not maintained over $1.00 U.S so opinions are welcomed if I am misunderstand this and any feedback is encouraged if you know how this listing notification is handled.

Couple of schools of thought on this one. It's probably a continuation of the stern message being sent with dissatisfaction of development, progress and schedule. Delay's and misteps have costs this company plenty and needless to say its shareholders also suffer. As pressure mounts changes are occurring but at a pace which doesn't keep with the share price demands. Let's hope that they got it right this time with the management structure and the new team delivers and quickly or we'll be scraping the pence from the bottom of this endless pool. Money is on the new team, but feel the Rolf and board need to introduce something new into the mix to shake it up a bit and get interest refocused so maybe add a new drug to the portfolio that could be commoditized immediately in the states adding fuel to the bottom line. Sell an asset to raise more capital or some other form of surprise. Slow bleed only helps me to buy more at lower cost, but also looks bad on total.

Does anyone have any specifics that they will be expecting from the upcoming conference call and earnings release scheduled for next week? I'm of the opinion and hope that the conference call and update on earnings will be "upbeat" and "provide guidance" on several items. Progress with Clinical Trials and profitable update for stateside sales are two of the items I trust will be discussed in detail. Again just my opinion and hope that we get clarity on these as well as recap on growth in 2017. Opinions from others here??

Probably for good reason. I can't imagine that the change in leadership wasn't in part over direction of the company and clinical trials My guess would be that Rolf, Craig and others have prepared a pretty good summary for next week, and we may even get some early indications on how the trials are going. I'd be very surprised if this didn't spike up just a but heading into the weekend. Good luck and I keep adding at these depressed levels.

Well it's turning up into the new quarter as I suspected, and agree ripe for bounce. I'd be looking for 50p by summer and 75-100p by Christmas. News flows over the summer and the annual report later this month should get good boost, and bottom may well already be in. We shall see and Craig has his stage later this month.

Change now that Q1 is over and positions for Q2 are to soon be taken by investors. News on the horizon for year end results, updates from the states and clinical progression... Bodes well for Q2